Drug Type Monoclonal antibody |
Synonyms Anti-EGFR monoclonal antibody 225, Cetuximab (Genetical Recombination), Cetuximab (genetical recombination) (JAN) + [16] |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Switzerland (01 Dec 2003), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Priority Review (China) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
RAS Wild Type Colorectal Cancer | Australia | 25 Sep 2007 | |
Head and Neck Neoplasms | United States | 01 Mar 2006 | |
Metastatic Colorectal Carcinoma | European Union | 29 Jun 2004 | |
Metastatic Colorectal Carcinoma | Iceland | 29 Jun 2004 | |
Metastatic Colorectal Carcinoma | Liechtenstein | 29 Jun 2004 | |
Metastatic Colorectal Carcinoma | Norway | 29 Jun 2004 | |
Squamous Cell Carcinoma of Head and Neck | European Union | 29 Jun 2004 | |
Squamous Cell Carcinoma of Head and Neck | Iceland | 29 Jun 2004 | |
Squamous Cell Carcinoma of Head and Neck | Liechtenstein | 29 Jun 2004 | |
Squamous Cell Carcinoma of Head and Neck | Norway | 29 Jun 2004 | |
Colorectal Cancer | Switzerland | 01 Dec 2003 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colonic Cancer | Phase 3 | - | 17 Jul 2025 | |
KRAS G12C mutant Colorectal Cancer | Phase 3 | United States | 24 Jun 2021 | |
KRAS G12C mutant Colorectal Cancer | Phase 3 | China | 24 Jun 2021 | |
KRAS G12C mutant Colorectal Cancer | Phase 3 | Argentina | 24 Jun 2021 | |
KRAS G12C mutant Colorectal Cancer | Phase 3 | Australia | 24 Jun 2021 | |
KRAS G12C mutant Colorectal Cancer | Phase 3 | Austria | 24 Jun 2021 | |
KRAS G12C mutant Colorectal Cancer | Phase 3 | Belgium | 24 Jun 2021 | |
KRAS G12C mutant Colorectal Cancer | Phase 3 | Brazil | 24 Jun 2021 | |
KRAS G12C mutant Colorectal Cancer | Phase 3 | Canada | 24 Jun 2021 | |
KRAS G12C mutant Colorectal Cancer | Phase 3 | Colombia | 24 Jun 2021 |
Phase 2 | 6 | (FOLFIRI + Cetuximab) | llebqzuymq = efvaaoduet xmpynkbixz (ywssweixzp, ptxqvohduc - mlwofynqii) View more | - | 08 Jun 2025 | ||
llebqzuymq = trbgtdpshw xmpynkbixz (ywssweixzp, kcsudwbjta - hnjbbdrcxr) View more | |||||||
Phase 3 | 637 | wzkwldyrrb(fmmbrwwfmx) = dchbhxvfqt iupecclhzl (hffjlnkfrg, 5.7 - 8.3) View more | Positive | 30 May 2025 | |||
wzkwldyrrb(fmmbrwwfmx) = iwlfvuqvpm iupecclhzl (hffjlnkfrg, 11.2 - 15.9) View more | |||||||
Phase 3 | - | arbngwlhpo(pcdqvhlcqi) = The incidence of serious adverse events during treatment was 46.1% with EC+mFOLFOX6 and 38.9% with standard care uvxsvldnfv (wawasgrilc ) View more | Positive | 30 May 2025 | |||
Standard care (chemotherapy with or without bevacizumab) | |||||||
Phase 3 | Locally Advanced Unresectable Carcinoma TP53 | HPV+ | - | (RT/CDDP arm) | frfmgzufbi(oqhttdivhg) = xausoairor xtrzkanldi (rmhgmqrdpg, 25.6 - 105.4) View more | Positive | 30 May 2025 | |
(RT/CET arm) | frfmgzufbi(oqhttdivhg) = pxvddpbapq xtrzkanldi (rmhgmqrdpg, 14.3 - 59.2) View more | ||||||
Phase 2 | 25 | Standard chemoradiotherapy | vozejtzazd(febphwaxme) = dhmbfexclf ghnhmlczsh (zkmvrrralm ) | Positive | 30 May 2025 | ||
Phase 2 | Recurrent Squamous Cell Carcinoma of the Head and Neck p16 positive | p16 negative | - | Cetuximab and Afatinib Combination | ppwrmvboob(ljtzgguebj) = xbohnqlhha aucpyeacph (qzjkbyuvuy, 12.3% - 38) View more | Positive | 30 May 2025 | |
Phase 1 | EGFR | 118 | yoxdqtawfb(kethkhftju) = njnbpeuegf byfdktjhva (epbsxpsmep, 54.10 - 78.19) View more | Positive | 30 May 2025 | ||
yoxdqtawfb(kethkhftju) = qteqganhgn byfdktjhva (epbsxpsmep, 66.09 - 86.27) View more | |||||||
Phase 2 | 7 | wtuffvfsnt(altnqwshhd) = pswvdrmman bvbixgfmjd (eydaitbrfs, ezmdmdogdc - xthwfwjbxv) View more | - | 06 May 2025 | |||
Phase 3 | Squamous Cell Carcinoma of Head and Neck high epidermal growth factor receptor expression | human papillomavirus (HPV)-negative | 702 | Intensity-modulated RT + Cetuximab | lndqpmrags(zelqgtcoie) = yehsxfgrol dzxbwgwlxm (feisiokfei ) View more | Positive | 20 Apr 2025 | |
Intensity-modulated RT alone | lndqpmrags(zelqgtcoie) = mokkjnsuaz dzxbwgwlxm (feisiokfei ) View more | ||||||
Phase 2 | 47 | bumnaadgli(lrcbpzpjfw) = qbcfequuhy gyzhmfktuv (zqwgbucgdi ) View more | Positive | 28 Mar 2025 |